FrancophonIA/ELRC3.0 huggingface dataset:
English: When co-administering inducers of metabolic enzymes, an increase in the daily dose of caspofungin to 70 mg, following the 70 mg loading dose, should be considered in adult patients (see section 4.2).
Slovenian: Pri sočasnem zdravljenju z induktorji presnovnih encimov moramo pri odraslih bolnikih razmisliti o povečanju dnevnega odmerka kaspofungina na 70 mg, po 70 mg uvajalnem odmerku (glejte poglavje
English: People who might get this type of infection include those who have just had an operation or those whose immune systems are weak.
Slovenian: Med tiste, ki bi lahko oboleli za temi okužbami, spadajo bolniki po kirurškem posegu in bolniki z oslabelim imunskim sistemom.
English: Co-administration with inducers of metabolic enzymes Limited data suggest that an increase in the daily dose of caspofungin to 70 mg, following the 70 mg loading dose, should be considered when co-administering caspofungin in adult patients with certain inducers of metabolic enzymes (see section 4.5).
Slovenian: Malo podatkov nakazuje, da je treba pri odraslih bolnikih v primeru sočasne uporabe kaspofungina z določenimi induktorji presnovnih encimov razmisliti o povečanju dnevnega odmerka kaspofungina na 70 mg (po 70-mg uvajalnem odmerku) (glejte poglavje 4.5).
English: Reconstitution of Caspofungin Accord
Slovenian: Priprava zdravila Kaspofungin Accord
English: Do not use this medicine after the expiry date which is stated on the carton and the vial .
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na viali (prvi dve številki pomenita mesec, naslednje štiri pa leto).
English: Anaphylaxis has been reported during administration of caspofungin.
Slovenian: Med uporabo kaspofungina so poročali o anafilaksiji.
English: There were 1,095 patients included in the primary Modified Intention-To-Treat (MITT) efficacy analysis of overall favourable response; caspofungin (33.9 %) was as effective as liposomal amphotericin B (33.7 %) [% difference 0.2 (95.2 % CI -5.6, 6.0)].
Slovenian: Kaspofungin (33,9 %) je bil enako učinkovit kot liposomski amfotericin B (33,7 %) [% razlike 0,2 (95,2-odstotni IZ -5,6, 6,0)].
English: • Itching, rash, skin redness or sweating more than usual
Slovenian: • srbenje, izpuščaj, pordelost kože ali čezmerno potenje
English: Common (≥1/100 to
Slovenian: Organski sistem Pogosti (≥ 1/100 do
English: Renal and urinary disorders renal failure, renal failure acute
Slovenian: Bolezni sečil odpoved ledvic, akutna odpoved ledvic
English: bag (or bottle) containing 250 mL of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride solution for infusion or Lactated Ringers solution for infusion.
Slovenian: intravensko vrečko (ali steklenico), ki vsebuje 250 ml 0,9 %, 0,45 % ali 0,225 % raztopine natrijevega klorida za infundiranje ali raztopine Ringerjevega laktata za infundiranje.
English: 0.45 %, or 0.225 % Sodium Chloride solution for infusion or Lactated Ringers solution for infusion, not to exceed a final concentration of 0.5 mg/mL.
Slovenian: Accord dodate zmanjšani količini 0,9 %, 0,45 % ali 0,225 % raztopine natrijevega klorida za infundiranje ali raztopine Ringerjevega laktata za infundiranje, vendar končna koncentracija ne sme preseči 0,5 mg/ml.
English: Aseptically transfer this volume (mL)c of reconstituted Caspofungin
Slovenian: Druga možnost je, da količino (ml)c pripravljene raztopine zdravila Kaspofungin
English: Caspofungin Accord 70 mg powder for concentrate caspofungin
Slovenian: Kaspofungin Accord 70 mg prašek za koncentrat za raztopino za infundiranje kaspofungin
English: Preparation of the 50 mg/m2 infusion for paediatric patients >3 months of age (using a 50-mg vial)
Slovenian: Priprava infuzije 50 mg/m2 za pediatrične bolnike, stare >3 mesece (z uporabo 50-mg viale)
English: The first study, which enrolled 82 patients between 2 to 17 years of age, was a randomized, doubleblind study comparing caspofungin (50 mg/m2 IV once daily following a 70-mg/m2 loading dose on
Slovenian: Prva študija je bila randomizirana, dvojno slepa študija z 82 bolniki, starimi od 2 do 17 let.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains: 70 mg caspofungin(as acetate).
Slovenian: NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena viala vsebuje 70 mg kaspofungina (v obliki acetata).
English: Development of in vitro resistance to caspofungin by Aspergillus species has been identified.
Slovenian: Pri Aspergillus sp. so in vitro ugotovili razvoj rezistence na kaspofungin.
English: Laboratory abnormalities in liver function tests have been seen in healthy volunteers and adult and paediatric patients treated with caspofungin.
Slovenian: Pri zdravih prostovoljcih in pri odraslih ter pediatričnih bolnikih, zdravljenih s kaspofunginom, so opazili nenormalne laboratorijske vrednosti izvidov jetrnih testov.
English: EU/1/15/1081/001
Slovenian: ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/15/1081/001
English: EU/1/15/1081/002
Slovenian: ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/15/1081/002
English: Remove the volume of medicine equal to the calculated daily maintenance dose (Step 1) from the vial.
Slovenian: Količino zdravila, ki ustreza izračunanemu dnevnemu vzdrževalnemu odmerku potegnite iz viale (1. korak).
English: Preparation of the 70 mg/m2 infusion for paediatric patients > 3 months of age (using a 70-mg vial)
Slovenian: Priprava infuzije 70 mg/m2 za pediatrične bolnike, stare >3 mesece (z uporabo 70-mg viale)
English: Caspofungin has been shown to cross the placental barrier in animal studies.
Slovenian: V študijah na živalih je kaspofungin prehajal skozi posteljico.
English: Refractoriness is defined as progression of infection or failure to improve after a minimum of
Slovenian: Nedovzetnost pomeni, da po najmanj 7 dneh prejemanja terapevtskih odmerkov učinkovitega protiglivnega zdravila okužba še vedno napreduje ali se stanje ne izboljša.
English: Forty-nine patients were enrolled and received caspofungin at 50 mg/m2 IV once daily following a 70-mg/m2 loading dose on
Slovenian: Bolniki so dobivali bodisi kaspofungin 50 mg enkrat na dan (po 70-mg uvajalnem odmerku) ali liposomski amfotericin B 3,0 mg/kg/dan.
English: Preparation of the 50 mg/m2 infusion for paediatric patients > 3 months of age (using a 70-mg vial)
Slovenian: Priprava infuzije 50 mg/m2 za pediatrične bolnike, stare >3 mesece (z uporabo 70-mg viale)
English: People who are at risk of getting a fungal infection include those who have just had an operation or those whose immune systems are weak.
Slovenian: Med bolnike s tveganjem za pojav glivne okužbe spadajo bolniki po kirurškem posegu in bolniki z oslabelim imunskim sistemom.
English: Preparation of the 70 mg/m2 infusion for paediatric patients >3 months of age (using a 50-mg vial)
Slovenian: Priprava infuzije 70 mg/m2 za pediatrične bolnike, stare >3 mesece (z uporabo 50-mg viale)
English: Aseptically transfer this volume (mL)c of reconstituted Caspofungin Accord to an IV bag (or bottle) containing 250 mL of 0.9 %, 0.45 %, or 0.225 % Sodium Chloride solution for infusion or Lactated Ringers solution for infusion.
Slovenian: To količino (ml)c pripravljene raztopine zdravila Kaspofungin Accord aseptično prenesite v intravensko vrečko (ali steklenico), ki vsebuje 250 ml 0,9 %, 0,45 % ali 0,225 % raztopine natrijevega klorida za infundiranje ali raztopine Ringerjevega laktata za infundiranje.
English: Remove the volume of medicinal product equal to the calculated daily maintenance dose (Step 1) from the vial.
Slovenian: Količino zdravila, ki ustreza izračunanemu dnevnemu vzdrževalnemu odmerku , potegnite iz viale (1. korak).
English: Remove the volume of medicine equal to the calculated loading dose (Step 1) from the vial.
Slovenian: Količino zdravila, ki ustreza izračunanemu uvajalnemu odmerku potegnite iz viale (1. korak).
English: Caspofungin Accord 50 mg powder for concentrate caspofungin
Slovenian: Kaspofungin Accord 50 mg prašek za koncentrat kaspofungin intravenska uporaba
English: In neonates and infants (<3 months) receiving caspofungin at 25 mg/m2 daily (corresponding mean daily dose of 2.1 mg/kg), caspofungin peak concentration (C1 hr) and caspofungin trough concentration (C24 hr) after multiple doses were comparable to that seen in adults receiving caspofungin at 50 mg daily.
Slovenian: (kar ustreza povprečnemu dnevnemu odmerku 2,1 mg/kg), sta bili največja koncentracija kaspofungina (C1 h) in koncentracija kaspofungina tik pred naslednjim odmerkom (C24 h) po večkratnih odmerkih podobni kot pri odraslih, ki so dobivali 50 mg kaspofungina na dan. Prvi dan je bila C1 h pri teh novorojenčkih in dojenčkih primerljiva, C24 h pa zmerno večja (36 %) v primerjavi z odraslimi.
English: • Itching, rash
Slovenian: • srbenje, izpuščaj
English: What measures are being taken to ensure the safe and effective use of Oxervate?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Oxervate?
English: The medicine is only used in adults with moderate or severe disease.
Slovenian: Zdravilo se uporablja samo pri odraslih z zmerno do hudo boleznijo.
English: The European Medicines Agency therefore decided that Oxervate's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor je zato zaključil, da so koristi zdravila Oxervate večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Oxervate can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Slovenian: Povzetek mnenja Odbora za zdravila sirote za zdravilo Oxervate je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: What benefits of Oxervate have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Oxervate izkazalo v študijah?
English: What is Oxervate and what is it used for?
Slovenian: Kaj je zdravilo Oxervate in za kaj se uporablja?
English: It is not intended to provide practical advice on how to use Oxervate.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: The recommended dose is 1 drop in the affected eye every 2 hours, 6 times per day.
Slovenian: Priporočeni odmerek je ena kapljica v prizadeto oko vsaki dve uri, šestkrat na dan. Zdravljenje mora trajati osem tednov.
English: For more information about treatment with Oxervate, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Oxervate preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: This is a summary of the European public assessment report (EPAR) for Oxervate.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Oxervate.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oxervate have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Oxervate upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: In the first study, 74% (37 out of 50) of patients treated with Oxervate for 8 weeks achieved complete healing of the eye's surface compared with 43% (22 out of 51) of patients treated with a dummy treatment containing the same eye drop formula but no active substance.
Slovenian: V prvi študiji je 74 % (37 od 50) bolnikov, ki so jih osem tednov zdravili z zdravilom Oxervate, doseglo popolno zacelitev očesne površine, v primerjavi s 43 % (22 od 51) bolnikov, zdravljenih z zdravilom brez zdravilne učinkovine, ki je bilo prav tako v obliki kapljic za oko, a ni vsebovalo zdravilne učinkovine.
English: The most common side effects with Oxervate (which may affect more than 1 in 100 people) are eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.
Slovenian: Najpogostejši neželeni učinki zdravila Oxervate (ki se lahko pojavijo pri več kot 1 bolniku od 100) so bolečine in vnetje očesa, povečano solzenje (solzne oči), bolečine v veki in občutek tujka v očesu.
English: The full EPAR for Oxervate can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Oxervate je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Why is Oxervate approved?
Slovenian: Zakaj je bilo zdravilo Oxervate odobreno?
English: Because the number of patients with neurotrophic keratitis is low, the disease is considered ‘rare', and Oxervate was designated an ‘orphan medicine' (a medicine used in rare diseases) on 14 December
Slovenian: Ker je bolnikov z nevrotrofičnim keratitisom malo, velja ta bolezen za redko, zato je bilo zdravilo Oxervate 14. decembra 2015 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: Oxervate has been shown to increase by around 30-40% the number of patients who achieve complete healing of the eye's surface when compared with eye drops containing no active substance.
Slovenian: Zdravilo Oxervate dokazano za 30-40 % poveča število bolnikov, ki dosežejo popolno zacelitev očesne površine, v primerjavi s kapljicami za oko, ki ne vsebujejo zdravilne učinkovine.
English: For practical information about using Oxervate, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Oxervate naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: The active substance in Oxervate, cenegermin, is a copy of a human growth factor called nerve growth factor.
Slovenian: Zdravilna učinkovina zdravila Oxervate, cenegermin, je kopija humanega rastnega dejavnika, imenovanega živčni rastni dejavnik.
English: What are the risks associated with Oxervate?
Slovenian: Kakšna tveganja so povezana z zdravilom Oxervate?
English: How is Oxervate used?
Slovenian: Kako se zdravilo Oxervate uporablja?
English: In the second study, figures were 70% (16 out of 23) with Oxervate and 29% (7 out of 24) with the dummy treatment.
Slovenian: V drugi študiji je bilo v skupini, ki je prejemala zdravilo Oxervate, takih bolnikov 70 % (16 od 23), v skupini, ki je prejemala zdravilo brez zdravilne učinkovine, pa 29 % (7 od 24).
English: Oxervate can only be obtained with a prescription and treatment should be started and supervised by an eye specialist.
Slovenian: Predpisovanje in izdaja zdravila Oxervate je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le specialist za očesne bolezni.
English: Oxervate contains the active substance cenegermin.
Slovenian: Zdravilo Oxervate vsebuje zdravilno učinkovino cenegermin.
English: For the full list of all side effects and restrictions with Oxervate, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Oxervate glejte navodilo za uporabo.
English: Side effects with Oxervate are mainly related to the eye, are mild or moderate in severity and resolve over time.
Slovenian: Neželeni učinki zdravila Oxervate so večinoma povezani z očesom, so blagi do zmerni in sčasoma izginejo.
English: Patients with neurotrophic keratitis have lower than normal levels of substances including growth factors that are normally supplied by the trigeminal nerve and which play an important role in the growth and survival of the cells of the eye's surface.
Slovenian: Pri bolnikih z nevrotrofičnim keratitisom so določene snovi v telesu, vključno z rastnimi dejavniki, ki jih običajno dovaja trigeminalni živec in ki imajo pomembno vlogo pri rasti in preživetju celic na očesni površini, v nižjih koncentracijah, kot je običajno.
English: Oxervate is a medicine used to treat neurotrophic keratitis, an eye condition in which damage to the trigeminal nerve supplying the surface of the eye causes loss of sensation and defects that do not heal naturally.
Slovenian: Oxervate je zdravilo, ki se uporablja za zdravljenje nevrotrofičnega keratitisa, očesne bolezni, pri kateri poškodovani trigeminalni živec, ki oživčuje površino očesa, povzroči neobčutljivost in okvare, ki se ne zacelijo po naravni poti.
English: How does Oxervate work?
Slovenian: Kako zdravilo Oxervate deluje?
English: When given as eye drops to patients with neurotrophic keratitis, cenegermin helps restore some of the normal healing processes in the eye and repair damage to the eye's surface associated with the condition.
Slovenian: Cenegermin v obliki kapljic za oko pri bolnikih z nevrotrofičnim keratitisom do določene mere pomaga obnoviti normalne procese celjenja v očesu in popraviti poškodbo očesne površine, povezano s tem stanjem.
English: Other information about Oxervate
Slovenian: Druge informacije o zdravilu Oxervate
English: Oxervate is available as eye drops.
Slovenian: Zdravilo Oxervate je na voljo v obliki kapljic za oko.
English: Oxervate has been shown to help heal damage to the eye's surface in 2 main studies involving a total of 204 adults with moderate or severe neurotrophic keratitis.
Slovenian: V dveh glavnih študijah, ki sta skupaj vključevali 204 odrasle bolnike z zmernim ali hudim nevrotrofičnim keratitisom, je zdravilo Oxervate dokazano pomagalo pri celjenju poškodb očesne površine.
English: This summary was last updated in 07-2017.
Slovenian: Oxervate EMA/330858/2017
English: Do not swallow them.
Slovenian: Ne pogoltnite jih.
English: These symptoms may vary from person to person.
Slovenian: Ti simptomi se lahko med posamezniki razlikujejo.
English: Just take the next dose at the scheduled time and continue as normal.
Slovenian: Naslednji odmerek vzemite ob načrtovanem času, nato pa nadaljujte kot običajno.
English: No interaction studies have been performed.
Slovenian: Študij medsebojnega delovanja niso izvajali.
English: After first opening: 18 weeks.
Slovenian: Po prvem odprtju: 18 tednov.
English: Physicians should periodically assess the need for continued treatment.
Slovenian: Zdravniki morajo redno ocenjevati potrebo po nadaljevanju zdravljenja.
English: However, treatment with Constella can be safely stopped at any time.
Slovenian: Vendar pa lahko zdravljenje z zdravilom Constella varno prekinete kadar koli.
English: Date of first authorisation: 26 November 2012 Date of latest renewal: 28 August 2017
Slovenian: Datum prve odobritve: 26. november 2012 Datum zadnjega podaljšanja: 28.
English: A risk to the newborns/infants cannot be excluded.
Slovenian: Tveganja za novorojenčka/dojenčka ne moremo izključiti.
English: For age related information, please see sections 4.2., 4.4., and 4.8.
Slovenian: Za informacije, povezane s starostjo, glejte poglavja 4.2., 4.4. in 4.8.
English: - if you or your doctor know that you have a blockage in your stomach or bowels.
Slovenian: - če vi ali vaš zdravnik veste, da imate blokado v želodcu ali črevesju.
English: - The other ingredients are :
Slovenian: Druge sestavine zdravila so:
English: The active metabolite was not detected in any of the 162 patients at any time point.
Slovenian: Aktivnega presnovka ni bilo v nobeni časovni točki mogoče zaznati pri nobenem od 162 bolnikov.
English: • feeling lightheaded after standing up quickly
Slovenian: • občutek vrtoglavice, če hitro vstanete
English: LS: Least Square CSBM: Complete Spontaneous Bowel Movement
Slovenian: LS: najmanjši kvadrat CSBM: popolne spontane defekacije
English: Approximately half of the diarrhoea episodes started within the first week of treatment.
Slovenian: Približno polovica epizod driske se je začela v prvem tednu zdravljenja.
English: Component of a multipack, can't be sold separately.
Slovenian: Del velikega pakiranja; ne sme se prodajati ločeno.
English: Side effects with frequency not known (frequency cannot be estimated from the available data):
Slovenian: Neželeni učinki z neznano pogostnostjo (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti):
English: Bloating (11-point NRS)
Slovenian: Napenjanje (11točkovni NRS)
English: As GC-C receptor is known to be overexpressed at early ages, children younger than 2 years may be particularly sensitive to linaclotide effects.
Slovenian: Ker je znano, da so receptorji GC-C v mladih letih čezmerno izraženi, so lahko otroci do 2. leta starosti še posebej občutljivi na učinke linaklotida.
English: Take special care if you are older than 65 years, as there is a higher risk you experience diarrhoea.
Slovenian: Zlasti bodite pazljivi, če ste starejši od 65 let, saj obstaja večja verjetnost za pojav driske.
English: Main secondary efficacy parameters
Slovenian: Glavni parametri sekundarne učinkovitosti
English: Linaclotide (N =805)
Slovenian: Linaklotid (n = 805)
English: Because these other diseases may have the same symptoms as IBS, it is important that you report any change or irregularity in symptoms to your doctor promptly.
Slovenian: Ker imajo lahko omenjene druge bolezni enake simptome kot sindrom razdražljivega črevesja, je pomembno, da o vseh spremembah ali nepravilnostih simptomov takoj poročate svojemu zdravniku.
English: What you need to know before you take Constella 3.
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Constella 3.
English: In the second clinical study (study 2), 800 patients were treated for 12 weeks, and then re-randomised for an additional 4 weeks treatment period.
Slovenian: V drugi klinični študiji (študija 2) so 800 bolnikov zdravili 12 tednov, nato pa so jih znova randomizirali za dodatno 4-tedensko obdobje zdravljenja.
English: The safety and efficacy of Constella in children aged 0 to18 years have not yet been established.
Slovenian: Varnost in učinkovitost zdravila Constella pri otrocih, starih od 0 do 18 let, nista bili dokazani.
English: These effects were reached at 1 week and sustained over the entire treatment periods.
Slovenian: Ti učinki so se pokazali v 1. tednu in so se ohranili skozi celotno obdobje zdravljenja.
English: In cases of severe or prolonged diarrhoea, absorption of other oral medicinal products may be affected.
Slovenian: V primeru hude ali dolgotrajnejše driske se lahko pojavi vpliv na absorpcijo drugih peroralnih zdravil.
English: This medicinal product should not be used in children and adolescents (see sections 4.4 and 5.1).
Slovenian: Zdravila se ne sme uporabljati pri otrocih in mladostnikih (glejte poglavji 4.4 in 5.1).
English: Do not use this medicine if you notice any signs of damage to the bottle or any change in the appearance of the capsules.
Slovenian: Ne uporabljate tega zdravila, če opazite kakršne koli znake poškodb plastenke ali spremembe v izgledu kapsul.
English: If you have very bad diarrhoea, the contraceptive pill may not work properly and the use of an extra method of contraception is recommended.
Slovenian: Če ste imeli zelo hudo drisko, kontracepcijska tabletka morda ne bo delovala pravilno, zato priporočamo uporabo dodatne kontracepcijske metode.
English: The efficacy of oral contraceptives may be reduced and the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception (see the prescribing information of the oral contraceptive).
Slovenian: Zmanjša se lahko učinkovitost peroralnih kontracepcijskih sredstev, zato priporočamo uporabo dodatne kontracepcijske metode za preprečitev morebitne neuspešnosti peroralne kontracepcije (glejte navodila za predpisovanje peroralnih kontracepcijskih sredstev).
English: Pharmacotherapeutic group: Drugs for constipation, other drugs for constipation, ATC Code: A06AX04
Slovenian: Farmakoterapevtska skupina: zdravila proti zaprtju, druga zdravila proti zaprtju, oznaka ATC: A06AX04
English: Once the bottle is opened, the capsules should be used within 18-weeks.
Slovenian: Po prvem odprtju plastenke je treba kapsule uporabiti v 18 tednih.